Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.ACGN · Entity 110652 | CHIEF OPERATING OFFICER | January 20, 2023 | February 02, 2023 |
| CalciMedica, Inc.GRAY · Entity 7804 | CTOO | December 08, 2020 | December 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date January 20, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2033-01-20 | Direct | 25,400 |
Reported balance
After 2023-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-20 · Grant · Acquired 25,400 · Balance 25,400 F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
CalciMedica, Inc.
Report date December 08, 2020 · Filed December 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.66 · Expires 2030-12-07 | Direct | 35,000 |
Reported balance
After 2020-12-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-08 · Grant · Acquired 35,000 · Balance 35,000 F1: The stock option vests as to 1/48 of the total shares on January 8, 2021 and each month thereafter until option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 1/48 of the total shares on January 8, 2021 and each month thereafter until option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2023 Filed Feb 2, 2023 20:12 UTC | Aceragen, Inc. ACGN · Entity 110652 | GrantStock Options (Right to Buy) · Derivative | 25,400 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001415889-23-001857 · form4-02032023_010231.xml · derivative · entry 1 Salain Daniel · CIK 0001824804 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 Underlying: Common Stock · 25,400 shares Expires 2033-01-20 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:46 UTC | Aceragen, Inc. ACGN · Entity 110652 | Exercise / conversionSeries Z Convertible Preferred Stock · Derivative | 22,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-005135 · tm233989-3_4seq1.xml · derivative · entry 2 Salain Daniel · CIK 0001824804 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,341,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F1 · kind: On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F1 · price: On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F1 · derivative.exercise_date: On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F1 · derivative.expiration_date: On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F2 · derivative.underlying_shares: Reflects a 1-for-17 reverse stock split, which became effective on January 17, 2023 at 4:59 pm Eastern Time. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:46 UTC | Aceragen, Inc. ACGN · Entity 110652 | Exercise / conversionCommon Stock | 1,341,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-005135 · tm233989-3_4seq1.xml · nonDerivative · entry 1 Salain Daniel · CIK 0001824804 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,469,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F1 · price: On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F2 · balance_after: Reflects a 1-for-17 reverse stock split, which became effective on January 17, 2023 at 4:59 pm Eastern Time. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 21:49 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantSeries Z Convertible Preferred Stock · Derivative | 22,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-104796 · tm2227191-8_4seq1.xml · derivative · entry 2 Salain Daniel · CIK 0001824804 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,810 Underlying: Common Stock · 22,810,000 shares Expires not disclosed F2 · derivative.exercise_price: Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations. F1 · kind: Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share ("Common Stock") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"). F1 · price: Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share ("Common Stock") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"). F2 · derivative.exercise_date: Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations. F2 · derivative.expiration_date: Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 21:49 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock, par value $0.001 | 2,171,214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-104796 · tm2227191-8_4seq1.xml · nonDerivative · entry 1 Salain Daniel · CIK 0001824804 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,171,214 F1 · kind: Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share ("Common Stock") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"). F1 · price: Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share ("Common Stock") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"). Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 22:10 UTC | CalciMedica, Inc. GRAY · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $23.66 | $0.00 |
DisclosureSEC source: 0001209191-20-062754 · doc4.xml · derivative · entry 1 Salain Daniel · CIK 0001824804 · CTOO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-07 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares on January 8, 2021 and each month thereafter until option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.